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Introduction
In patients receiving nutritional support, the delivery of nutri-
ents via the enteral route is more effective and economical than
via the parenteral route.1–3 During recent years, many investi-
gations of enteral nutrition have focused on the ability to
modulate the immune response to injury via specially formu-
lated enteral diets enriched with arginine, glutamine and
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omega-3 fatty acids.4–7 Enteral immunonutrition is standard-
formula enteral nutrition supplemented with specific com-
pounds, such as arginine, glutamine, omega-3 fatty acids
and RNA, which have particular ability to improve immune
defensive and intestinal barrier function and to modulate the
inflammatory response.8–10 Currently, one enteral immuno-
nutritional product is available for clinical use in China. It
contains high-dose glutamine, arginine and omega-3 fatty
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acids, which enhance the effect of nutritional support.
We designed a prospective randomized clinical trial to test
whether enteral immunonutrition improved defence mecha-
nisms and modulated inflammatory action after major sur-
gery compared with standard enteral nutrition.
Patients and methods
From September 2002 to August 2003, 40 patients undergo-
ing major elective surgery for gastric carcinoma were included
in this study. There were 28 males and 12 females with a mean
age of 59.03 ( 12.55 years (range, 31–75 years). The protocol
was approved by the ethics committee of our hospital. All
patients were required to sign a written informed consent
form before entering the trial. Patients were excluded from the
study if they had previously had radiotherapy or treatment
with immunosuppressive drugs or had AIDS, endocrine or
metabolic disorders, any known allergic disease, sepsis, pre-
existing severe chronic disease or congestive heart failure. The
patients were randomly divided into an immunonutrition
group and a standard nutrition group, each of 20 patients.
Those in the immunonutrition group received an enteral
immunonutrition product enriched with arginine, glutamine
and omega-3 fatty acids (Stresson®, Nutricia China, Shanghai,
China), while the standard nutrition group received standard
enteral nutrition (Nutrison®; Nutricia China) (Table 1).
Enteral nutrition was administered by nasoenteric tube.
The enteral feeding tube was inserted through a nostril and
advanced by the surgeon to 10 cm beyond the jejunojejunal or
gastrojejunal anastomosis during the operation. On postop-
erative Day 2, patients received 25% of the planned caloric goal,
based on 30 non-protein calories/kg/day. On postoperative
Day 3, 50% of the planned caloric goal was given. From post-
operative Day 4 until the end of the study, patients received
100% of the planned caloric goal. There were no differences in
preoperative clinical profiles of patients and postoperative
management between the two groups, except the formula of
enteral nutrition, which was similar apart from the three
specific nutrients mentioned above.
In both groups, peripheral venous blood was collected to
determine plasma levels of albumin, transferrin and pre-
albumin on postoperative Days 0, 5 and 9. Another blood
sample was obtained on postoperative Days 0, 1 and 9 to de-
tect immunoglobulin (Ig) A, IgG, IgM, CD4 and CD8 cell
counts, the ratio of CD4/CD8, interleukin (IL)-2, IL-6 and tu-
mour necrosis factor (TNF)-_.
Results
The two formulas were tolerated well and the postoperative
process was uneventful. No intestinal fistula, respiratory fail-
ure or liver dysfunction developed after surgery. The regimens
did not influence complication frequency or clinical recovery.
The serum albumin level did not change significantly
during the postoperative period, and no difference was ob-
served between the two groups (Table 2). A significant differ-
ence in prealbumin and transferrin levels was found between
the two groups on Day 9. Although the pattern of change was
the same in both groups, the levels of prealbumin and transfer-
rin in the experimental group were higher than those in the
control group.Table 1. Main differences in composition of two nutritional
formulas (per L)
Stresson® Nutrison®
Total energy (kcal) 1,250 1,000
Total protein (g) 75.0 (24 EN%) 40.0 (16 EN%)
Arginine (g) 8.9 1.6
Glutamine (g) 13.0 4.0
Fats (g) 4.17 (30 EN%) 3.89 (35 EN%)
Long-chain fatty acids (g) 24.5 38.9
Medium-chain fatty acids (g) 17.2 0
Omega-6:omega-3 fatty acids 3.45:1 5:1
Carbohydrates (g) 145 (46 EN%) 123 (49 EN%)
Fibre (g) 9 50
Vitamin E (mg) 49.2 8.1
Osmolarity (mOsm/L) 380 250
EN% = percentage of total energy.
Table 2. Variations in serum proteins
Albumin Prealbumin Transferrin
(g/L) (mg/L) (mg/L)
Stresson®
   Day 0 36.15 ( 3.60 197.9 ( 24.05 2.41 ( 0.56
   Day 5 33.75 ( 3.39 148.5 ( 22.22 1.85 ( 0.43
   Day 9 36.05 ( 2.95 194.0 ( 39.82 2.07 ( 0.52
Control
   Day 0 36.80 ( 4.76 187.2 ( 51.79 2.15 ( 0.54
   Day 5 33.30 ( 4.05 142.6 ( 38.50 1.51 ( 0.34
   Day 9 35.26 ( 2.96   162.5 ( 45.73* 1.60 ( 0.42†
*p < 0.05, †p < 0.01 compared with control group.
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function would be affected by glutamine deficiency. In vitro
experiments show that glutamine is required for increased
phagocytosis, RNA production and IL-1 secretion by
macrophages.19 Polymorphonuclear cells after burn injury
also appear to have more effective bactericidal function in
the presence of glutamine.20
Arginine stimulates secretion of a variety of hormones,
such as growth hormone, glucagons and insulin, each of
which has profound modulatory effects on immune re-
sponse.21 It is a precursor for synthesis of polyamines and
nucleic acids, both of which are indispensable substances for
cell proliferation and differentiation.22 Furthermore, arginine
is a direct precursor of nitrogen oxide and some of its function
is mediated by the L-arginine-nitric oxide pathway.9 Arginine
also increases lymphocyte mitogenic and allogenic responses
and natural killer cell cytotoxicity. It can enhance IL-2 produc-
tion and receptor activity, which are involved in reprioritization
of protein synthesis.23
The role fatty acids play in modulating the immune re-
sponse is based on their effects on the structural and func-
tional integrity of the cell membrane, intercellular signal trans-
duction and synthesis of the eicosanoids (important immune
mediators).10 By replacing other fatty acids with omega-3 fatty
acids, membrane flexibility is enhanced, which is essential for
phagocytosis and expression of IL-2 receptors.24 In vivo experi-
ments have shown that omega-3 fatty acids reduce IL-1, IL-2,
IL-6 and TNF production by peripheral monocytes.25 In con-
trast to these immune-enhancing effects, omega-3 fatty acids
used for eicosanoid synthesis are immunologically less potent
mediators than their omega-6 counterparts.10
Inflammation is essential for healing, immune processes
and successful recovery after injury. However, uncontrolled
Plasma immunoglobulin concentrations, CD4 and CD8
cell counts and cytokine concentrations were comparable in
the two groups preoperatively. However, on Day 9, serum
immunoglobulin level, CD4 cell counts, CD4/CD8 ratio and
IL-2 were higher in the immunonutrition group than in the
control group, whereas IL-6 and TNF-_ levels were signifi-
cantly lower in the immunonutrition group (Table 3). These
results indicate that immunonutrition can increase immu-
nity and modify the inflammation triggered by surgical
intervention.
Discussion
Surgical intervention usually results in further impairment of
immune defence mechanisms and altered inflammatory re-
sponses in patients who have underlying disorders of nutri-
tional and immune function.11–13 Evidence increasingly shows
that nutritional support reduces postoperative complications
and improves surgical outcomes.14,15 The most rational ap-
proach may be enteral immunonutrition support. Some inves-
tigations show that enteral immunonutrition has pharmaco-
logical effects on immune and inflammatory functions.4,5,16
Compared with the standard nutritional formula, Stresson®
contains enriched arginine (8.9 g/L), glutamine (13 g/L) and
an appropriate ratio of omega-6/omega-3 fatty acids, which
are involved in all aspects of the immune system.
Glutamine is a major and favourite fuel for lymphocytes
and macrophages. It is a precursor for nucleotide synthesis
and acts as a precursor for glutathione, a major link in the
antioxidative defence system. Lymphocytes have high glutami-
nase activity and high glutamine utilization, both of which
increase after a mitogenic stimulus.8,17,18 Thus, lymphocyte
Table 3. Variations in immune and inflammatory factors
Experimental group Control group
Day 0 Day 1 Day 9 Day 0 Day 1 Day 9
IgA (g/L) 12.33 ( 0.81 11.90 ( 0.54 13.04 ( 0.48 12.44 ( 1.01 11.95 ( 0.88 1 12.54 ( 0.91*
IgG (g/L) 10.53 ( 1.39 19.20 ( 1.16 13.22 ( 1.34 10.76 ( 1.40 19.17 ( 1.15  112.18 ( 1.29*
IgM (g/L) 11.42 ( 0.29 11.07 ( 0.44 11.71 ( 0.42 11.39 ( 0.24 10.95 ( 0.43  111.45 ( 0.40*
CD4 141.07 ( 13.75 33.56 ( 6.02 48.04 ( 6.71 41.19 ( 8.78 32.86 ( 8.40 140.37 ( 7.21†
CD8 24.88 ( 3.67 23.15 ( 7.95 21.68 ( 8.54 25.15 ( 6.63 23.55 ( 6.72  23.29 ( 4.04
CD4/CD8 11.67 ( 0.56 11.57 ( 0.52 12.92 ( 2.49 11.72 ( 0.44 11.51 ( 0.58  111.77 ( 0.37*
IL-2 (pg/mL) 284.21 ( 73.89 290.34 ( 74.96 368.56 ( 65.15 257.22 ( 58.22 280.34 ( 49.21 1317.70 ( 48.71†
IL-6 (pg/mL) 1268.68 ( 108.50 1537.01 ( 107.26 1411.13 ( 124.79 1299.22 ( 128.69 1584.01 ( 161.11 11519.33 ( 122.89†
TNF-_ (pg/mL) 280.22 ( 44.41 1373.58 ( 120.61 320.59 ( 83.44 284.27 ( 45.46 1386.05 ( 118.02 1439.74 ( 98.17†
*p < 0.05, †p < 0.01 compared with experimental group. Ig = immunoglobulin; IL = interleukin; TNF = tumour necrosis factor.
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systemic inflammatory responses lead to organ dysfunction
and adverse outcome.26 Further, it has been suggested that
injury alters the balance of protein synthesis by switching
from constitutive to acute-phase proteins through the release
of pro-inflammatory cytokines such as TNF-_ and IL-6.27 This
may be associated with a rapid decrease in nitrogen balance,
with loss of lean body mass and with catabolic response.
In our study, we observed that immunonutritional sup-
port increased serum immunoglobulin levels and enhanced
the levels of CD4 cells and the CD4/CD8 ratio compared with
standard enteral nutrition. We also found that immunonu-
tritional support successfully increased the serum level of
IL-2 and decreased the serum level of IL-6 and TNF-_. The
positive effect of immunonutrition on immunity and inflam-
mation is due to its high doses of glutamine, arginine and
omega-3 fatty acids, which greatly affect non-specific and
specific immunity.
Conclusion
Our results demonstrate that immunonutrition is superior to
standard nutrition in restoring immunity and modulating
inflammatory reaction in patients who have undergone major
surgery, which implies that enteral immunonutrition may be
a promising form of nutritional support.
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